{"transactions":[{"id":4626471,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T23:37:56.000Z","date":"2026-09-24","kind":"sale","planned":false,"acquired":false,"shares":156,"price":7.0587,"value":1101.1572,"ownership":{"direct":true},"balance_after":589518,"source":{"system":"sec-edgar","filing":"0001493152-26-044207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1834105/000149315226044207/ownership.xml","form_type":"4"}},{"id":4626470,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T23:37:56.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":27,"price":6.95,"value":187.65,"ownership":{"direct":true},"balance_after":589674,"source":{"system":"sec-edgar","filing":"0001493152-26-044207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1834105/000149315226044207/ownership.xml","form_type":"4"}},{"id":4626469,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T23:37:56.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":723,"price":0.55,"value":397.65,"ownership":{"direct":true},"balance_after":589701,"source":{"system":"sec-edgar","filing":"0001493152-26-044207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1834105/000149315226044207/ownership.xml","form_type":"4"}},{"id":825017,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":55274,"kind":"person","name":"Macko Todd D","position":1,"cik":"0001830744","reported_name":"Macko Todd D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T21:06:34.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":43400,"price":0.5615,"value":24369.1,"ownership":{"direct":true},"balance_after":155122,"source":{"system":"sec-edgar","filing":"0001493152-26-013708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1830744/000149315226013708/ownership.xml","form_type":"4"}},{"id":825016,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":55274,"kind":"person","name":"Macko Todd D","position":1,"cik":"0001830744","reported_name":"Macko Todd D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T21:06:34.000Z","date":"2026-03-25","kind":"sale","planned":false,"acquired":false,"shares":1600,"price":0.6008,"value":961.28,"ownership":{"direct":true},"balance_after":198122,"source":{"system":"sec-edgar","filing":"0001493152-26-013708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1830744/000149315226013708/ownership.xml","form_type":"4"}},{"id":827948,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":55983,"kind":"person","name":"Grady Jason","position":1,"cik":"0001782482","reported_name":"Grady Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-25T19:55:39.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":0.6501,"value":32505.0,"ownership":{"direct":true},"balance_after":250182,"source":{"system":"sec-edgar","filing":"0001493152-26-012746","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782482/000149315226012746/ownership.xml","form_type":"4"}},{"id":949060,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:25:05.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":45400,"price":0.5403,"value":24529.62,"ownership":{"direct":true},"balance_after":545024,"source":{"system":"sec-edgar","filing":"0001493152-26-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315226000635/ownership.xml","form_type":"4"}},{"id":949059,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:25:05.000Z","date":"2025-05-22","kind":"sale","planned":false,"acquired":false,"shares":115600,"price":0.5491,"value":63475.96,"ownership":{"direct":true},"balance_after":590424,"source":{"system":"sec-edgar","filing":"0001493152-26-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315226000635/ownership.xml","form_type":"4"}},{"id":1134350,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-27T20:35:00.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":45400,"price":0.5403,"value":24529.62,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-012502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225012502/ownership.xml","form_type":"4"}},{"id":1134349,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-27T20:35:00.000Z","date":"2025-05-22","kind":"sale","planned":false,"acquired":false,"shares":115600,"price":0.5491,"value":63475.96,"ownership":{"direct":true},"balance_after":45400,"source":{"system":"sec-edgar","filing":"0001641172-25-012502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225012502/ownership.xml","form_type":"4"}},{"id":1177173,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T01:59:28.000Z","date":"2025-04-04","kind":"sale","planned":false,"acquired":false,"shares":890800,"price":0.9486,"value":845012.88,"ownership":{"direct":true},"balance_after":161100,"source":{"system":"sec-edgar","filing":"0001641172-25-003114","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225003114/ownership.xml","form_type":"4"}},{"id":1176491,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-04-07T21:18:49.000Z","date":"2025-04-03","kind":"sale","planned":false,"acquired":false,"shares":351555,"price":0.495,"value":174019.725,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 3, 2025, Alset International Limited sold 351,555 shares of the Issuer's common stock at a weighted average sale price of $0.495. This transaction was executed in multiple trades at prices ranging from $0.46 to $0.57. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-003021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225003021/ownership.xml","form_type":"4"}},{"id":1177488,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-04","kind":"sale","planned":false,"acquired":false,"shares":180000,"price":0.96,"value":172800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On April 4, 2025, Global Biomedical Pte. Ltd. sold 180,000 shares of the Issuer's common stock at a weighted average sale price of $0.96 This transaction was executed in multiple trades at prices ranging from $0.93 to $0.997. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177487,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-03","kind":"sale","planned":false,"acquired":false,"shares":273286,"price":0.779,"value":212889.794,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On April 3, 2025, Global Biomedical Pte. Ltd. sold 273,286 shares of the Issuer's common stock at a weighted average sale price of $0.779. This transaction was executed in multiple trades at prices ranging from $0.75 to $0.84. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177486,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-03","kind":"sale","planned":false,"acquired":false,"shares":351631,"price":0.579,"value":203594.349,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On April 3, 2025, Alset Inc. sold 351,631 shares of the Issuer's common stock at a weighted average sale price of $0.579. This transaction was executed in multiple trades at prices ranging from $0.50 to $0.73. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177485,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":382427,"price":0.583,"value":222954.941,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On April 2, 2025, Alset Inc. sold 382,427 shares of the Issuer's common stock at a weighted average sale price of $0.583. This transaction was executed in multiple trades at prices ranging from $0.57 to $0.63. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":351631,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177484,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":2349,"price":0.673,"value":1580.877,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 2, 2025, Alset International Limited sold 2,349 shares of the Issuer's common stock at a weighted average sale price of $0.673. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":351555,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177483,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":0.674,"value":134800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 2, 2025, Alset International Limited sold 200,000 shares of the Issuer's common stock at a weighted average sale price of $0.674. This transaction was executed in multiple trades at prices ranging from $0.67 to $0.80. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":353904,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1177482,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-04T21:15:33.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":0.581,"value":174300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $0.581. This transaction was executed in multiple trades at prices ranging from $0.551 to $0.607. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited."}],"balance_after":553904,"source":{"system":"sec-edgar","filing":"0001641172-25-002819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002819/ownership.xml","form_type":"4"}},{"id":1182951,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-03T01:01:08.000Z","date":"2025-04-01","kind":"sale","planned":false,"acquired":false,"shares":1176918,"price":1.08,"value":1271071.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On April 1, 2025, Alset Inc. sold 1,176,918 shares of the Issuer's common stock at a weighted average sale price of $1.08. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."}],"balance_after":734058,"source":{"system":"sec-edgar","filing":"0001641172-25-002479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002479/ownership.xml","form_type":"4"}},{"id":1182950,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-03T01:01:08.000Z","date":"2025-04-01","kind":"sale","planned":false,"acquired":false,"shares":650000,"price":1.447,"value":940550.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 1, 2025, Alset Inc. sold 650,000 shares of the Issuer's common stock at a weighted average sale price of $1.447. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."}],"balance_after":1910976,"source":{"system":"sec-edgar","filing":"0001641172-25-002479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002479/ownership.xml","form_type":"4"}},{"id":1182949,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2025-04-03T01:01:08.000Z","date":"2025-04-01","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":0.982,"value":392800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2025, Alset International Limited sold 400,000 shares of the Issuer's common stock at a weighted average sale price of $0.9816. This transaction was executed in multiple trades at prices ranging from $0.6938 to $1.36. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."}],"balance_after":853904,"source":{"system":"sec-edgar","filing":"0001641172-25-002479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002479/ownership.xml","form_type":"4"}},{"id":1182948,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":24553,"kind":"person","name":"Chan Heng Fai Ambrose","position":1,"cik":"0001261725","reported_name":"Chan Heng Fai Ambrose","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25403,"kind":"organization","name":"Alset International Ltd","position":2,"cik":"0001660984","reported_name":"Alset International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":7148,"kind":"organization","name":"Alset Inc.","position":3,"cik":"0001750106","reported_name":"Alset Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-03T01:01:08.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":1.028,"value":308400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 31, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $1.028. This transaction was executed in multiple trades at prices ranging from $0.82 to $1.29. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc."}],"balance_after":1253904,"source":{"system":"sec-edgar","filing":"0001641172-25-002479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261725/000164117225002479/ownership.xml","form_type":"4"}},{"id":1189247,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-27","kind":"sale","planned":false,"acquired":false,"shares":47681,"price":2.5011,"value":119254.9491,"ownership":{"direct":true},"balance_after":1051800,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1189246,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":9858,"price":3.15,"value":31052.7,"ownership":{"direct":true},"balance_after":1099481,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1189245,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":48281,"price":3.1292,"value":151080.9052,"ownership":{"direct":true},"balance_after":1109339,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1189244,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":166600,"price":3.3004,"value":549846.64,"ownership":{"direct":false,"nature":"By DSS BioHealth Security, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This entity is a wholly-owned subsidiary of DSS, Inc."}],"balance_after":1178882,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1189243,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":166600,"price":3.3004,"value":549846.64,"ownership":{"direct":false,"nature":"By DSS BlockChain Security, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This entity is a wholly-owned subsidiary of DSS, Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1189242,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:25:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":166600,"price":3.3004,"value":549846.64,"ownership":{"direct":false,"nature":"By DSS Securities, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This entity is a wholly-owned subsidiary of DSS, Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-001312","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225001312/ownership.xml","form_type":"4"}},{"id":1194142,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-25T00:00:38.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":53280,"price":4.68,"value":249350.4,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001641172-25-000403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225000403/ownership.xml","form_type":"4"}},{"id":1194141,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-25T00:00:38.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":200,"price":1.55,"value":310.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":53280,"source":{"system":"sec-edgar","filing":"0001641172-25-000403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225000403/ownership.xml","form_type":"4"}},{"id":1194140,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-25T00:00:38.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":20,"price":2.9,"value":58.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":53080,"source":{"system":"sec-edgar","filing":"0001641172-25-000403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000164117225000403/ownership.xml","form_type":"4"}},{"id":1338581,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":85298,"kind":"person","name":"Heuszel Frank D","position":1,"cik":"0001748704","reported_name":"Heuszel Frank D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-09T16:05:17.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":2.2578,"value":1128.9,"ownership":{"direct":true},"balance_after":97344,"source":{"system":"sec-edgar","filing":"0001493152-24-049260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748704/000149315224049260/ownership.xml","form_type":"4"}},{"id":1344311,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":85298,"kind":"person","name":"Heuszel Frank D","position":1,"cik":"0001748704","reported_name":"Heuszel Frank D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-03T21:51:36.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":2.61,"value":1305.0,"ownership":{"direct":true},"balance_after":96844,"source":{"system":"sec-edgar","filing":"0001493152-24-048579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748704/000149315224048579/ownership.xml","form_type":"4"}},{"id":1344310,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":85298,"kind":"person","name":"Heuszel Frank D","position":1,"cik":"0001748704","reported_name":"Heuszel Frank D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-03T21:49:22.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":2.59,"value":1295.0,"ownership":{"direct":true},"balance_after":96344,"source":{"system":"sec-edgar","filing":"0001493152-24-048576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748704/000149315224048576/ownership.xml","form_type":"4"}},{"id":1344309,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":85298,"kind":"person","name":"Heuszel Frank D","position":1,"cik":"0001748704","reported_name":"Heuszel Frank D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-03T21:49:22.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":550,"price":2.625,"value":1443.75,"ownership":{"direct":true},"balance_after":95844,"source":{"system":"sec-edgar","filing":"0001493152-24-048576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748704/000149315224048576/ownership.xml","form_type":"4"}},{"id":1355260,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:33:56.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":3.017,"value":15085.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":53100,"source":{"system":"sec-edgar","filing":"0001493152-24-047410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224047410/ownership.xml","form_type":"4"}},{"id":1355259,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:33:56.000Z","date":"2024-11-13","kind":"sale","planned":false,"acquired":false,"shares":200,"price":2.8,"value":560.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":58100,"source":{"system":"sec-edgar","filing":"0001493152-24-047410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224047410/ownership.xml","form_type":"4"}},{"id":1355258,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T21:33:56.000Z","date":"2024-11-12","kind":"sale","planned":false,"acquired":false,"shares":500,"price":2.757,"value":1378.5,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":58300,"source":{"system":"sec-edgar","filing":"0001493152-24-047410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224047410/ownership.xml","form_type":"4"}},{"id":1402879,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-19T23:07:23.000Z","date":"2024-09-18","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.33,"value":2330.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":58800,"source":{"system":"sec-edgar","filing":"0001493152-24-037196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224037196/ownership.xml","form_type":"4"}},{"id":1404200,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-19T00:53:50.000Z","date":"2024-09-17","kind":"purchase","planned":false,"acquired":true,"shares":7800,"price":2.4,"value":18720.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":57800,"source":{"system":"sec-edgar","filing":"0001493152-24-037044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224037044/ownership.xml","form_type":"4"}},{"id":1404199,"issuer":{"id":7209,"kind":"organization","name":"IMPACT BIOMEDICAL INC.","symbol":"IBO"},"owners":[{"id":8811,"kind":"organization","name":"DSS, INC.","symbol":"DSS","position":1,"cik":"0000771999","reported_name":"DSS, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-19T00:53:50.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.69,"value":134500.0,"ownership":{"direct":false,"nature":"By Sentinel Brokers Company, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sentinel Brokers Company, Inc. is a majority owned subsidiary of DSS, Inc."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001493152-24-037044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224037044/ownership.xml","form_type":"4"}}]}